Actinium Pharmaceuticals Inc (ATNM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Actinium Pharmaceuticals Inc (ATNM) has a cash flow conversion efficiency ratio of -2.548x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.87 Million) by net assets ($2.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Actinium Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Actinium Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Actinium Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Actinium Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Actinium Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Artea SA
PA:ARTE
|
-0.078x |
|
Microequities Asset Management Group Ltd
AU:MAM
|
0.219x |
|
Brand 24 SA
WAR:B24
|
0.338x |
|
Revoil S.A
AT:REVOIL
|
-0.040x |
|
Jin Yang Pharmaceutical Co. Ltd
KQ:007370
|
-0.022x |
|
Unisync Corp
TO:UNI
|
0.082x |
|
INITECH Co. Ltd
KQ:053350
|
-0.003x |
|
GROUP PAREF INH. EO 25
F:G5I
|
N/A |
Annual Cash Flow Conversion Efficiency for Actinium Pharmaceuticals Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Actinium Pharmaceuticals Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Actinium Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.83 Million | $-24.58 Million | -3.138x | -210.78% |
| 2024-12-31 | $32.76 Million | $-33.07 Million | -1.010x | +22.41% |
| 2023-12-31 | $36.38 Million | $-47.34 Million | -1.301x | -1100.72% |
| 2022-12-31 | $66.48 Million | $8.64 Million | 0.130x | +145.83% |
| 2021-12-31 | $73.55 Million | $-20.87 Million | -0.284x | +19.52% |
| 2020-12-31 | $61.32 Million | $-21.62 Million | -0.353x | +90.73% |
| 2019-12-31 | $5.64 Million | $-21.46 Million | -3.802x | -62.89% |
| 2018-12-31 | $8.81 Million | $-20.57 Million | -2.334x | -48.06% |
| 2017-12-31 | $13.67 Million | $-21.55 Million | -1.577x | -36.57% |
| 2016-12-31 | $18.01 Million | $-20.79 Million | -1.154x | -36.80% |
| 2015-12-31 | $21.97 Million | $-18.54 Million | -0.844x | -111.31% |
| 2014-12-31 | $-1.92 Million | $-14.35 Million | 7.463x | +84.98% |
| 2013-12-31 | $-1.56 Million | $-6.29 Million | 4.035x | +188.68% |
| 2012-12-31 | $1.15 Million | $-5.21 Million | -4.550x | -71087.78% |
| 2011-12-31 | $-84.33K | $539.00 | -0.006x | +92.28% |
| 2010-12-31 | $-94.62K | $7.83K | -0.083x | -142.45% |
| 2009-12-31 | $-96.29K | $-18.78K | 0.195x | +3.32% |
| 2008-12-31 | $-73.96K | $-13.96K | 0.189x | -59.53% |
| 2007-12-31 | $-33.20K | $-15.49K | 0.467x | -38.81% |
| 2006-12-31 | $-18.40K | $-14.03K | 0.763x | -- |
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular… Read more